CureGene has dosed the first participant in an Australian Phase 1 trial of CG-0416, moving its oral liver-targeted thyroid hormone receptor beta agonist from an increasingly ambitious preclinical programme into the first human test of whether the molecule’s tissue-selective design can produce useful metabolic activity without excessive systemic thyroid-hormone effects. The randomized, double-blind and placebo-controlled study will evaluate single and multiple ascending doses in healthy participants, examining safety, tolerability, pharmacokinetics and pharmacodynamics before the company considers expansion into patients with metabolic disease. Clinical-trial listings indicate a planned enrollment of approximately 64 participants aged 18 to 60, divided across eight dose cohorts, with the study being conducted at Nucleus Network in Melbourne.
The programme sits at the intersection of two increasingly valuable metabolic markets. CureGene describes CG-0416 as a liver-activated prodrug being developed for metabolic dysfunction-associated steatotic liver disease and MASH, while simultaneously positioning its metabolic effects as potentially useful in obesity and in combination with GLP-1 receptor agonists. The company’s most eye-catching claims, including semaglutide-comparable weight reduction with substantially greater preservation of muscle mass, come from animal studies rather than humans, making the Phase 1 transition especially important because the programme now has to establish that its selective liver activation behaves in people the way CureGene’s preclinical models suggest.
Why is CureGene trying to activate THR-β mainly inside the liver?
Thyroid hormones influence energy expenditure, lipid metabolism, heart rate, bone turnover and numerous other physiological processes, which makes indiscriminate activation a poor therapeutic strategy for chronic metabolic disease. The beta isoform of the thyroid hormone receptor is expressed strongly in the liver, however, and selective THR-β activation can increase hepatic lipid metabolism without reproducing every systemic effect associated with thyroid hormone. The clinical validation of THR-β in MASH has already reduced target risk, but developers still compete on how selectively the active drug reaches the liver and how much exposure occurs in other tissues.
CG-0416 has been designed as a prodrug that is intended to release its active metabolite preferentially after reaching the liver. CureGene says this architecture generates high intrahepatic exposure while keeping peripheral concentrations lower, a profile intended to preserve the desired effects on liver fat, cholesterol metabolism and metabolic signaling while reducing unwanted activation elsewhere. The company reported in earlier preclinical work that hepatic concentrations of active metabolite were substantially higher than peripheral exposure, but those findings remain nonclinical until human pharmacokinetic data establish how selective the metabolism actually is in participants.
This distinction becomes particularly important because the first human trial is not yet designed to prove MASH resolution or meaningful weight loss. Investigators are initially asking whether exposure increases predictably with dose, whether pharmacodynamic markers move in the expected direction and whether thyroid-related, cardiovascular or other adverse effects appear before reaching exposures believed to be therapeutically useful. A favorable Phase 1 result would therefore validate the prodrug architecture more directly than it would validate CureGene’s eventual efficacy claims.
Why is muscle preservation becoming a competitive issue in obesity drug development?
Modern incretin medicines can produce weight reductions that were difficult to achieve pharmacologically only a few years ago, but total body-weight loss does not consist entirely of adipose tissue. Some lean mass is typically lost alongside fat, which has intensified interest in whether next-generation treatments can improve body composition rather than simply maximize the number displayed on a scale. The issue could become particularly important in older adults and people who begin treatment with limited muscle reserves, where additional loss of lean tissue may affect physical function.
CureGene says CG-0416 produced an unusually fat-selective pattern of weight reduction in diet-induced obese mice. At ObesityWeek 2025, the company reported that approximately 95% of weight lost in one preclinical setting came from fat tissue, while it characterized semaglutide-treated animals as losing a larger proportion of muscle. Earlier EASL data also described lower muscle loss and reductions in liver lipid accumulation, but these were animal experiments and should not be translated into an expectation that humans taking CG-0416 will reproduce the same body-composition profile.
The Phase 1 programme can begin testing whether the molecule alters metabolic parameters without creating obvious tolerability concerns, but meaningful claims around muscle preservation will require human body-composition data over a longer treatment period. If the effect survives clinical testing, CureGene could pursue a differentiation strategy based less on absolute weight loss and more on the composition and metabolic quality of that loss.
Could CG-0416 complement GLP-1 medicines rather than compete directly with them?
CureGene is pursuing both possibilities. The company describes CG-0416 as capable of producing weight reduction as a monotherapy in preclinical models, but it also emphasizes combination data suggesting that THR-β activation may complement GLP-1-mediated appetite reduction. Mechanistically, the two strategies approach metabolic disease from different directions: GLP-1 receptor agonists strongly influence appetite, satiety and glucose regulation, while a liver-focused THR-β therapy is intended to alter hepatic lipid metabolism and energy handling more directly.
That could become commercially important as obesity treatment moves toward combination regimens. Once several highly effective incretin drugs compete on weight reduction, pharmaceutical developers will increasingly search for agents that improve another component of metabolic health, address patients who cannot tolerate GLP-1 therapy or help patients maintain body composition while receiving strong appetite-suppressing treatment. MASH provides another rationale because liver disease frequently coexists with obesity and diabetes, potentially allowing one mechanism to address hepatic pathology while another drives greater overall weight reduction.
Combination development will nevertheless require more than mechanistic complementarity. Adding another chronic medicine increases cost, complexity and the opportunity for drug-related adverse events, so CG-0416 would need to provide a measurable benefit beyond what modern incretin therapy already achieves. CureGene’s preclinical combination data can justify studying that question, but human dose-ranging and efficacy studies will determine whether the effect is large enough to support another drug in the regimen.
What will the 64-participant Phase 1 study tell CureGene first?
The immediate test is whether CG-0416 behaves as a controllable oral medicine. The trial is designed around ascending single and multiple doses, allowing investigators to characterize exposure, accumulation and pharmacodynamic activity while watching for adverse events as doses increase. Clinical-trial records describe healthy adults rather than a large obesity or MASH population, so substantial clinical weight-loss conclusions would be premature even if some body-weight or lipid changes occur during the study.
Human pharmacokinetics will also test one of CureGene’s most important engineering claims. If liver-targeted activation works as intended, the company should be able to reach biologically active hepatic exposure without producing the degree of systemic exposure that would undermine the rationale for building a prodrug in the first place. Pharmacodynamic measurements involving lipids, glucose metabolism and thyroid-related signals can then indicate whether the molecule is operating through the expected pathway.
The programme is consequently entering its most important transition so far. Animal models allowed CureGene to frame CG-0416 as an oral therapy capable of addressing liver fat, body weight and muscle preservation simultaneously, but Phase 1 will decide whether the underlying chemistry translates into human pharmacology. Only after that question is answered does the larger challenge begin: proving that activating THR-β in the liver can deliver a clinically meaningful metabolic advantage in a market where approved incretin therapies have already set a very high efficacy bar.
